Initial Therapy: Emflaza and Agamree
Covered when ALL of the following criteria are met. Initial approval is for 6 months.
ALL of the following
Diagnosis of Duchenne muscular dystrophy (DMD) confirmed by genetic testing.
Member is 2 years of age or older.
Prescribed by or in consultation with a provider who specializes in the treatment of DMD or neuromuscular disorders.
ONE of the following
Weight gain defined as at least a 10% increase in weight from baseline after 6 months of prednisone therapy.
Severe psychiatric adverse effects, such as aggression, abnormal behavior, or mood swings, that would necessitate a prednisone dose reduction.
Continuation Therapy: Emflaza and Agamree
Extension requests for up to 12 months will be approved when the member demonstrates continued benefit from therapy, including at least one of the following.
ONE of the following
Increase in muscle strength, pulmonary function tests, or timed function tests.
Decrease in adverse effects experienced while receiving prednisone.
New York Medicaid: Exon-Skipping Therapies
For New York Medicaid, pharmacy-benefit medications are covered and billed to the New York State Fee-for-Service (FFS) program. These medications include products obtained through a retail or specialty pharmacy, including self-administered injectable products, and are subject to FFS clinical criteria, including coverage, quantity limits, step therapy, and prior authorization. Pharmacy benefit information is available at https://www.emedny.org/info/fullform.pdf. Requests are reviewed when ALL of the following criteria are met based on New York State Department of Health Fee-for-Service criteria. Approval is for 6 months.
ALL of the following
Member has a diagnosis of Duchenne muscular dystrophy (DMD).
Genetic testing confirms that the member's DMD gene mutation is amenable to exon 45, 51, or 53 skipping.
Documentation confirms a stable dose of corticosteroids before starting therapy, or provides a documented reason why the member is not receiving corticosteroids.
Documentation indicates kidney function testing was completed before starting therapy, except for eteplirsen.
New York Medicaid: Elevidys
For New York Medicaid, requests for Elevidys are reviewed when ALL of the following criteria are met based on New York State Department of Health Fee-for-Service criteria.
ALL of the following
Member has a diagnosis of Duchenne muscular dystrophy (DMD).
Genetic testing confirms the DMD gene mutation.
Member is at least 4 years old.
Documentation confirms that the member does not have a deletion in exon 8 and/or exon 9 of the DMD gene.
Elevidys
Elevidys may be considered for coverage when ALL of the following criteria are met. Coverage is contingent on eligibility at the time of infusion.
ALL of the following
Member is at least 4 years old.
Member has a confirmed diagnosis of Duchenne muscular dystrophy (DMD).
Genetic testing confirms the DMD gene mutation.
Documentation confirms that the member does not have a deletion in exon 8 and/or exon 9 of the DMD gene.
Member has anti-AAVrh74 total binding antibody titers <1:400.
Age, dose, frequency of dosing, and/or duration of therapy outside FDA-approved package labeling are excluded from coverage.
Combination therapy with other corticosteroids is excluded from coverage.
Exondys 51 is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit, including improved motor function, has not been demonstrated.
Vyondys 53 is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit has not been confirmed.
Viltepso is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit has not been confirmed.
Amondys 45 is excluded for all diagnoses, including Duchenne muscular dystrophy, because clinical benefit has not been confirmed.
Elevidys is excluded for non-ambulatory members with Duchenne muscular dystrophy because clinical benefit has not been confirmed.